IBio
iBio, Inc. is a biotechnology company specializing in plant-based protein expression technologies for the development and manufacturing of vaccines and therapeutic proteins. The company offers contract development and manufacturing services to various collaborators and third-party customers in the United States. Its lead therapeutic candidate, IBIO-100, is in investigational new drug development for systemic scleroderma and idiopathic pulmonary fibrosis. iBio is also advancing multiple vaccine candidates, including IBIO-200 and IBIO-201 for preventing severe acute respiratory syndrome coronavirus 2, and IBIO-400 for classical swine fever. The company utilizes its proprietary iBioLaunch and iBioModulator platforms to enable rapid production of biologics, facilitating applications for both proprietary and biosimilar products. iBio operates in two segments: Biopharmaceuticals, which focuses on product candidates, and Bioprocessing activities, which encompasses various manufacturing services. Through collaborations with organizations like Planet Biotechnology and Texas A&M University, iBio enhances its capabilities in developing therapeutics for infectious diseases and other health challenges. The company is headquartered in New York, New York.
Top Regions
Top Stages
2 past transactions
RubrYc Therapeutics
Acquisition in 2022
RubrYc Therapeutics Inc. is a biotechnology company based in San Carlos, California, founded in 2017. The company focuses on the integration of chemistry and computation to decode protein interfaces, which facilitates the discovery of antibody-based drugs with selectivity for specific epitopes. By leveraging advancements in molecular library synthesis and massively parallel screening, RubrYc Therapeutics aims to revolutionize the design and development of therapeutic antibodies. Its innovative approach provides partners in the biotherapeutic field with tools to accelerate preclinical antibody discovery while reducing the risks typically associated with traditional drug discovery methods.
RubrYc Therapeutics
Series A in 2021
RubrYc Therapeutics Inc. is a biotechnology company based in San Carlos, California, founded in 2017. The company focuses on the integration of chemistry and computation to decode protein interfaces, which facilitates the discovery of antibody-based drugs with selectivity for specific epitopes. By leveraging advancements in molecular library synthesis and massively parallel screening, RubrYc Therapeutics aims to revolutionize the design and development of therapeutic antibodies. Its innovative approach provides partners in the biotherapeutic field with tools to accelerate preclinical antibody discovery while reducing the risks typically associated with traditional drug discovery methods.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.